NEFL and Parkinson disease: However, this hypothetical panel should include not only biomarkers that are strictly related to PD pathophysiology (e.g., α-synuclein, lysosomal enzymes, LRRK2, DJ1, and inflammatory markers), but also those biomarkers that are more involved in PD progression (e.g., Aβ42, tau proteins and NfL).